Skip to main content
Clinical Trials/NCT00370799
NCT00370799
Completed
Early Phase 1

A Randomized, Prospective, Double-Blind Controlled Evaluation of the Effectiveness of Caudal Epidural Injections in Lumbar Disc Herniations, Spinal Stenosis, Discogenic Pain, and Post-Lumbar Laminectomy Syndrome

Pain Management Center of Paducah1 site in 1 country240 target enrollmentJanuary 2007

Overview

Phase
Early Phase 1
Intervention
Caudal epidural injection
Conditions
Low Back Pain
Sponsor
Pain Management Center of Paducah
Enrollment
240
Locations
1
Primary Endpoint
To evaluate for differences between the patients in various groups in the physical function and pain at 1, 3, 6, and 12 months post treatment
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

To demonstrate clinically significant improvements or lack thereof in the caudal epidural patients with our without steroids.

To evaluate differences in outcomes in patients receiving steroids compared to those patients randomized to the local anesthetic group who did not receive steroids.

To assess improvements among patients and compare steroid groups with each other and local anesthetic group.

To evaluate and compare the adverse event profile in all patients

Detailed Description

Patients with chronic low back pain of at least 6 months duration, non-responsive to conservative management with NSAIDS, physical therapy or chiropractic treatment exercises. A single-center, prospective, controlled, double blinded, randomized study of patients in 4 groups. * Group 1. local anesthetics only * Group 2. local anesthetic with 6mg of non-particulate Celestone * Group 3. local anesthetic with 6 mg of brand name Celestone * Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol All patients will be unblinded in 12 months. Non-responsive patients will be unblinded after 3 months and will be crossed over to a different group

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
March 2010
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Laxmaiah Manchikanti, MD

Medical Director

Pain Management Center of Paducah

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age
  • History of chronic, function-limiting low back pain of at least 6 months duration
  • Able to give voluntary, written informed consent to participate,
  • Able to understand the investigation, cooperate with the procedures, and willing to return for follow-up
  • No recent surgical procedures within last three months

Exclusion Criteria

  • Cauda Equina symptoms and/or compressive radiculopathy
  • Narcotic use of no greater than 100mg/day hydrocodone, 60mg Methadone. or 100mg morphine
  • Uncontrolled major Depression or uncontrolled psychiatric disorder
  • Uncontrolled or acute medical illnesses
  • Chronic severe conditions that could interfere with outcome assessments
  • Women who are pregnant or lactating
  • Subjects who have participated in a clinical study with an investigational product within 30 days of enrollment
  • Patients with multiple complaints involving concomitant hip osteoarthritis
  • Inability to achieve proper positioning and inability to understand informed consent and protocol
  • History of adverse reaction to local anesthetic or anti-inflammatory drugs and history of gastrointestinal bleeding or ulcers

Arms & Interventions

local anesthetic

Group 1. local anesthetics only

Intervention: Caudal epidural injection

Local anesthetic with generic Celestone

Group 2. local anesthetic with 6mg of non-particulate Celestone

Intervention: Caudal Epidural Injection with generic Celestone

Local anesthetic with Celestone

Group 3. local anesthetic with 6 mg of brand nameCelestone

Intervention: Caudal Epidural Injection with Celestone

Local anesthetic with DepoMedrol

Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol

Intervention: Caudal Epidural Injection with DepoMedrol

Outcomes

Primary Outcomes

To evaluate for differences between the patients in various groups in the physical function and pain at 1, 3, 6, and 12 months post treatment

Time Frame: 1,3,6,12 months

Secondary Outcomes

  • To assess adverse events in all four groups.(1,3,6,12 months)

Study Sites (1)

Loading locations...

Similar Trials